US2014154801A1PendingUtilityA1

Endocrine precursor cells, pancreativ hormone-expressing cells and methos of production

60
Assignee: VIACYTE INCPriority: Mar 2, 2006Filed: Nov 5, 2013Published: Jun 5, 2014
Est. expiryMar 2, 2026(expired)· nominal 20-yr term from priority
Inventors:Kevin Allen D'AmourAnne BangEmmanuel E. Baetge
A61P 3/10A61P 5/48A61P 1/18C12N 5/0676C12N 2500/38C12N 2501/415C12N 2501/58C12N 2501/119C12N 2501/41C12N 5/0678C12N 2501/335C12N 2506/02C12N 2501/10C12N 2501/12C12N 2501/33A61K 35/39C12N 2501/42C12N 2501/105C12N 2501/16C12N 2501/115C12N 2501/999C12N 2501/15C12N 2501/385C12N 2501/734
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed herein are cell cultures and enriched cell populations of endocrine precursor cells, immature pancreatic hormone-expressing cells and mature pancreatic hormone-expressing cells. Also disclosed herein are methods of producing such cell cultures and cell populations.

Claims

exact text as granted — not AI-modified
1 - 20 . (canceled) 
     
     
         21 . A population of cells expressing markers characteristic of the pancreatic endoderm lineage, wherein said markers are pancreatic duodenal homeobox 1(PDX1) and NKX6 transcription factor related locus 1 (NKX6.1) or pancreas specific transcription factor 1a(PTF1A). 
     
     
         22 . The cell population of claim  1 , wherein said population is derived from a human pluripotent stem cell. 
     
     
         23 . The cell population of claim  1 , wherein said population is in contact with a gamma secretase inhibitor. 
     
     
         24 . The cell population of claim  1 , wherein said population is in contact with a retinoid. 
     
     
         25 . The cell population of claim  1 , wherein said population is in contact with noggin. 
     
     
         26 . The cell population of claim  1 , wherein said markers are PDX1 and NKX6.1. 
     
     
         27 . The cell population of claim  1 , wherein said markers are PDX1, NKX6.1 and PTF1A. 
     
     
         28 . The cell population of claim  1 , wherein the population does not substantially express INS or GCG. 
     
     
         29 . An in vitro cell culture comprising pancreatic endoderm cells that express a marker selected from the group consisting of PDX1, NKX6.1 and PTF1A. 
     
     
         30 . The cell culture of  claim 29 , wherein said cells are in contact with a retinoid. 
     
     
         31 . The cell culture of  claim 29 , wherein said cells are in contact with noggin. 
     
     
         32 . The cell culture of  claim 29 , wherein said pancreatic endoderm cells express PDX1 and NKX6.1. 
     
     
         33 . The cell culture of  claim 29 , wherein said cells are in contact with a gamma secretase inhibitor. 
     
     
         34 . The cell culture of  claim 29 , wherein the pancreatic endoderm cells do not substantially express INS or GCG. 
     
     
         35 . An in vitro differentiated population of pancreatic endoderm cells obtained from the differentiation of pluripotent stem cells, wherein the population expresses PDX1 and NKX6.1 or PTF1A. 
     
     
         36 . The cell population of  claim 35 , wherein said pluripotent stem cell is an embryonic stem cell. 
     
     
         37 . The cell population of  claim 35 , wherein said population is in contact with a gamma secretase inhibitor. 
     
     
         38 . The cell population of  claim 35 , wherein said population is in contact with a retinoid. 
     
     
         39 . The cell population of  claim 35 , wherein said population is in contact with noggin. 
     
     
         40 . The cell population of  claim 35 , wherein said population does not substantially express INS or GCG.

Join the waitlist — get patent alerts

Track US2014154801A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.